Journal Watch · Annals of the Rheumatic Diseases · 2026
EULAR recommendations for the management of Behçet's syndrome: 2025 update.
Early use of monoclonal antibodies against TNFα is encouraged in patients with organ or life-threatening manifestations.<h4>Conclusions</h4>These recommendations, which were updated based on new evidence and expert opinion, provide guidance for all stakeholders involved in the management of patients with Behçet's syndrome to improve the quality of care of these patients.
TL;DR
Early use of monoclonal antibodies against TNFα is encouraged in patients with organ or life-threatening manifestations.<h4>Conclusions</h4>These recommendations, which were updated based on new evidence and expert opinion, provide guidance for all stakeholders involved in the management of patients with Behçet's syndrome to improve the quality of care of these patients.
Key findings
- Apremilast and immunosuppressives such as tumour necrosis factor alpha (TNFα) inhibitors are recommended for refractory patients.
- For patients with organ involvement, more aggressive treatment with glucocorticoids and immunosuppressives is recommended for rapid induction of remission.
- Early use of monoclonal antibodies against TNFα is encouraged in patients with organ or life-threatening manifestations.<h4>Conclusions</h4>These recommendations, which were updated based on new evidence and expert opinion, provide guidance for all stakeholders involved in the management of patients with Behçet's syndrome to improve the quality of care of these patients.
What they did
The updated recommendations were voted, and the levels of evidence and levels of agreement were determined.<h4>Results</h4>The updated recommendations consist of 5 overarching principles and 12 recommendations that were tabulated according to organ involvement. Among the 12 recommendations, 1 was a new recommendation, 7 recommendations were modified, and only the wording was changed in 4 recommendations. The overarching principles focus on the importance of recognising the relapsing and remitting disease course and individualising treatment according to disease activity and prognostic risk factors, and emphasise the importance of a multidisciplinary approach, patient education, and shared decision making for optimal care. For mucocutaneous and joint involvement, colchicine is recommended as the first-line treatment modality.
Full abstract (original)
Background: <h4>Objectives</h4>This study aims to update the European Alliance of Associations for Rheumatology (EULAR) recommendations for the management of Behçet's syndrome according to the updated EULAR standard operating procedures.<h4>Methods</h4>The task force comprised 29 members from 11 countries, including 19 rheumatologists, 2 ophthalmologists, 1 dermatologist, 1 gastroenterologist, 1 neurologist, 1 health professional, 2 patient research partners, and 2 Emerging EUlar NETwork members. Research questions were proposed by the task force through a Delphi survey and formulated into patients, interventions, comparison, and outcomes (PICO) questions for the systematic literature review. The results of the systematic literature review were discussed among the task force members. Previous recommendations and overarching principles were modified, and new recommendations were developed as needed.
What they did: The updated recommendations were voted, and the levels of evidence and levels of agreement were determined.<h4>Results</h4>The updated recommendations consist of 5 overarching principles and 12 recommendations that were tabulated according to organ involvement. Among the 12 recommendations, 1 was a new recommendation, 7 recommendations were modified, and only the wording was changed in 4 recommendations. The overarching principles focus on the importance of recognising the relapsing and remitting disease course and individualising treatment according to disease activity and prognostic risk factors, and emphasise the importance of a multidisciplinary approach, patient education, and shared decision making for optimal care. For mucocutaneous and joint involvement, colchicine is recommended as the first-line treatment modality.
Results & conclusions: Apremilast and immunosuppressives such as tumour necrosis factor alpha (TNFα) inhibitors are recommended for refractory patients. For patients with organ involvement, more aggressive treatment with glucocorticoids and immunosuppressives is recommended for rapid induction of remission. Early use of monoclonal antibodies against TNFα is encouraged in patients with organ or life-threatening manifestations.<h4>Conclusions</h4>These recommendations, which were updated based on new evidence and expert opinion, provide guidance for all stakeholders involved in the management of patients with Behçet's syndrome to improve the quality of care of these patients.
Abstract © the authors / Annals of the Rheumatic Diseases (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1016/j.ard.2026.02.009 · PubMed 41876291.
Why it matters for pharma & biotech
- Directly relevant to teams in antibody / ADC therapeutics, small-molecule drug discovery — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
- Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Modalities & themes detected: antibody / ADC therapeutics · small-molecule drug discovery
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
- As a review, this paper synthesises prior studies rather than reporting new experimental data; weight it accordingly.
- The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.
Frequently asked questions
What did this Annals of the Rheumatic Diseases study find?
Early use of monoclonal antibodies against TNFα is encouraged in patients with organ or life-threatening manifestations.<h4>Conclusions</h4>These recommendations, which were updated based on new evidence and expert opinion, provide guidance for all stakeholders involved in the management of patients with Behçet's syndrome to improve the quality of care of these patients.
What type of study is this?
It is a review / perspective, published in Annals of the Rheumatic Diseases in 2026. The updated recommendations were voted, and the levels of evidence and levels of agreement were determined.<h4>Results</h4>The updated recommendations consist of 5 overarching principles and 12 recommendations that were tabulated according to organ involvement.
Where can I read the original paper?
The original is at the publisher via DOI 10.1016/j.ard.2026.02.009. PubMed ID: 41876291. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/eular-recommendations-for-the-management-of-behcet-s-syndrome-2025-updat-602009/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides